0.6724
price down icon2.98%   -0.0285
 
loading
前日終値:
$0.7009
開ける:
$0.7
24時間の取引高:
42,555
Relative Volume:
0.07
時価総額:
$16.53M
収益:
$411.00K
当期純損益:
$-4.85M
株価収益率:
-1.5282
EPS:
-0.44
ネットキャッシュフロー:
$-4.88M
1週間 パフォーマンス:
+10.21%
1か月 パフォーマンス:
-35.85%
6か月 パフォーマンス:
-22.24%
1年 パフォーマンス:
-69.64%
1日の値動き範囲:
Value
$0.6642
$0.70
1週間の範囲:
Value
$0.555
$0.7197
52週間の値動き範囲:
Value
$0.46
$2.295

Lexaria Bioscience Corp Stock (LEXX) Company Profile

Name
名前
Lexaria Bioscience Corp
Name
セクター
Healthcare (1119)
Name
電話
250-765-6424
Name
住所
100 - 740 MCCURDY ROAD, KELOWNA
Name
職員
7
Name
Twitter
Name
次回の収益日
2025-07-28
Name
最新のSEC提出書
Name
LEXX's Discussions on Twitter

LEXX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
LEXX
Lexaria Bioscience Corp
0.6642 17.44M 411.00K -4.85M -4.88M -0.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.73 118.84B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
799.51 81.61B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
425.17 53.69B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
813.10 49.49B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
176.43 37.34B 447.02M -1.18B -906.14M -6.1812

Lexaria Bioscience Corp (LEXX) 最新ニュース

pulisher
Jan 02, 2026

Growth Value: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainable2025 Key Lessons & Technical Pattern Based Buy Signals - moha.gov.vn

Jan 02, 2026
pulisher
Jan 02, 2026

Lexaria Bioscience (LEXX) Expected to Announce Earnings on Friday - Defense World

Jan 02, 2026
pulisher
Jan 01, 2026

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - New Castle News

Jan 01, 2026
pulisher
Dec 31, 2025

Lexaria releases additional results from Phase 1b study GLP-1-H24-4 - Yahoo Finance

Dec 31, 2025
pulisher
Dec 30, 2025

Lexaria’s Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform - TipRanks

Dec 30, 2025
pulisher
Dec 30, 2025

Lexaria Bioscience (LEXX) Reports Promising Results from Phase 1 - GuruFocus

Dec 30, 2025
pulisher
Dec 30, 2025

Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan

Dec 30, 2025
pulisher
Dec 30, 2025

Lexaria Bioscience (NASDAQ:LEXX) Shares Up 5.5% – Here’s What Happened - Defense World

Dec 30, 2025
pulisher
Dec 28, 2025

Sentiment Review: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainableMarket Performance Report & Stepwise Trade Execution Plans - moha.gov.vn

Dec 28, 2025
pulisher
Dec 27, 2025

How geopolitical tensions affect Lexaria Bioscience Corp stock2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn

Dec 27, 2025
pulisher
Dec 27, 2025

Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN

Dec 27, 2025
pulisher
Dec 26, 2025

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga

Dec 26, 2025
pulisher
Dec 26, 2025

Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN

Dec 26, 2025
pulisher
Dec 26, 2025

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright By Investing.com - Investing.com South Africa

Dec 26, 2025
pulisher
Dec 26, 2025

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright - Investing.com

Dec 26, 2025
pulisher
Dec 26, 2025

LEXX: HC Wainwright & Co. Lowers Price Target to $1.50, Maintains Buy Rating | LEXX Stock News - GuruFocus

Dec 26, 2025
pulisher
Dec 24, 2025

LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Research Tree

Dec 24, 2025
pulisher
Dec 24, 2025

Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch

Dec 24, 2025
pulisher
Dec 23, 2025

Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN

Dec 23, 2025
pulisher
Dec 23, 2025

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga

Dec 23, 2025
pulisher
Dec 23, 2025

Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 - TipRanks

Dec 23, 2025
pulisher
Dec 23, 2025

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Investing News Network

Dec 23, 2025
pulisher
Dec 23, 2025

Experimental oral GLP-1 pill cuts side effects by nearly half in trial - Stock Titan

Dec 23, 2025
pulisher
Dec 21, 2025

Is Lexaria Bioscience Corp. stock resilient to inflationJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - Улправда

Dec 21, 2025
pulisher
Dec 20, 2025

What momentum indicators show for Lexaria Bioscience Corp. stockPortfolio Growth Summary & AI Powered Market Trend Analysis - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Will Lexaria Bioscience Corp. stock deliver better than expected guidanceQuarterly Profit Review & Safe Capital Investment Plans - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Is Lexaria Bioscience Corp. stock a buy on dipsJuly 2025 Technicals & AI Optimized Trading Strategy Guides - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Portfolio Recap: What valuation multiples suggest for Lexaria Bioscience Corp. Equity Warrant stockBreakout Watch & Fast Entry and Exit Trade Plans - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Setup Watch: Is Lexaria Bioscience Corp. stock resilient to inflationSell Signal & Consistent Profit Trade Alerts - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

How geopolitical tensions affect Lexaria Bioscience Corp. stockJuly 2025 Short Interest & Free Expert Verified Stock Movement Alerts - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Will Lexaria Bioscience Corp. Equity Warrant stock benefit from AI adoptionWeekly Profit Summary & Risk Managed Trade Strategies - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Published on: 2025-12-19 15:15:39 - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Published on: 2025-12-19 14:32:21 - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationWeekly Earnings Recap & Weekly Top Stock Performers List - Улправда

Dec 19, 2025
pulisher
Dec 18, 2025

Momentum Shift: Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationJuly 2025 Breakouts & Daily Risk Controlled Trade Plans - Улправда

Dec 18, 2025
pulisher
Dec 18, 2025

Lexaria Bioscience Corp (LEXX) is a good investment, but the stock may be undervalued - uspostnews.com

Dec 18, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience Corp. (LEXX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Dec 16, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience Secures $3.5 Million in Capital Through Registered Direct Offering - citybuzz -

Dec 16, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience closes $3.5 million registered direct offering - Investing.com

Dec 16, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience closes $3.5 million registered direct offering By Investing.com - Investing.com Canada

Dec 16, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience (NASDAQ: LEXX) details approximately $3.5 million financing terms - Stock Titan

Dec 16, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Bluefield Daily Telegraph

Dec 16, 2025

Lexaria Bioscience Corp (LEXX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$40.99
price up icon 0.90%
$33.78
price up icon 2.01%
$109.69
price up icon 2.81%
$98.46
price up icon 0.37%
biotechnology ONC
$333.25
price up icon 4.15%
$176.39
price up icon 0.96%
大文字化:     |  ボリューム (24 時間):